Tiziana Life Sciences Ltd. announced that a reduction in activated microglia, as seen in six-month Positron Emission Tomography (PET) scans, has now been observed in a total of five of the six patients with non-active secondary-progressive multiple sclerosis (na-SPMS) treated with intranasal foralumab in its Expanded Access Program (EAP). Activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory and neurodegenerative diseases including multiple sclerosis, Alzheimer?s disease, and amyotrophic lateral sclerosis, or ALS.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.63 USD | +1.17% | -10.36% | +12.50% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+12.50% | 62.46M | |
+26.31% | 44.96B | |
-0.90% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.47% | 26.08B | |
-21.29% | 19.03B | |
+6.03% | 12.75B | |
+28.51% | 12.06B | |
-3.35% | 11.75B |
- Stock Market
- Equities
- TLSA Stock
- News Tiziana Life Sciences Ltd
- Tiziana Announces Positive Qualitative Six-Month Pet Scan Results with Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed with Non-Active Secondary Progressive MS (Na-SPMS)